[Therapy of carcinomatous peritonitis by the angiogenesis inhibitor TNP-470 in mice: analysis of timing and doses for intraperitoneal administration].
In order to perform therapy for carcinomatous peritonitis by a new angiogenesis inhibitor, TNP-470, we investigated the effective timing and the optimal doses for intraperitoneal administration using two mice models. In both carcinomatous peritonitis models caused by M 5076 tumor and B 16 melanoma, the early administration of TNP-470 within one week after tumor inoculation extended the survival times of the mice receiving the drugs, whereas the administration of TNP-470 one week or later after inoculation did not affect the survival time. However, there were significant differences in the effective therapeutic doses of TNP-470 between the two models. It is important to select the best timing and doses for intraperitoneal administration of TNP-470 based on the state of angiogenesis and the sensitivity of the tumor tissues to TNP-470.
Tsujimoto
H
H
First Dept. of Surgery, Kyoto Prefectural University of Medicine.
Osaki
K
K
Ohyama
T
T
Sakakibara
T
T
Ohgaki
M
M
Imanishi
T
T
Yamasaki
J
J
Shirasu
M
M
Shimotsuma
M
M
Hagiwara
A
A
D000818:Animals; D000903:Antibiotics, Antineoplastic / Q000008:administration & dosage*; D003510:Cyclohexanes; D007263:Infusions, Parenteral; D008297:Male; D008546:Melanoma, Experimental / Q000473:pathology*; D051379:Mice; D008810:Mice, Inbred C57BL; D009361:Neoplasm Invasiveness; D000077609:O-(Chloroacetylcarbamoyl)fumagillol; D010538:Peritonitis / Q000188:drug therapy* / Q000473:pathology; D012513:Sarcoma, Experimental / Q000473:pathology*; D012717:Sesquiterpenes / Q000008:administration & dosage*
D000903:Antibiotics, Antineoplastic; D003510:Cyclohexanes; D012717:Sesquiterpenes; D000077609:O-(Chloroacetylcarbamoyl)fumagillol